Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2006

View Archived Issues

Positive findings from phase II study of inhaled Parkinson's disease product VR-040

Introgen to incorporate use of biomarkers in Advexin data analysis

Takeda sees progress on many fronts in first quarter

Phase II trials under way at VIA Pharmaceuticals for new antiatherosclerotic candidate

Cephalon will not pursue Sparlon following not approvable letter

Medicure acquires Aggrastat from MGI Pharma

Enrollment reactivated in phase III trial of Riquent

Abeille submits AB-1001 phase III study protocol for FDA review

Phase III SLE program announced for LymphoStat-B

RegeneRx receives grant to support phase II epidermolysis bullosa trial of TB4

Phase I findings indicate AVR-118 safe in patients with type 2 diabetes

New antiinfective agents reported in recent patent literature

Recent patents reveal novel agents for treating endocrine-related disorders

Recent Janssen and Taiho patents describe new compounds for urological disorders

Two additional patients treated in phase IIa Oxycyte study

Positive findings for application of XP-828L platform in atopic dermatitis

U.K. clearance for phase I study of obesity drug ATHX-105

Clinical program begins for oral PXD-101

Arisaph completes second closing of financing round

Positive phase I data for Actyve transdermal drug delivery for infertility

Oscient grants Canadian Factive commercialization rights to Abbott

Bristol-Myers Squibb report on new selective and potent NHE-1 inhibitor

Bioluminescence imaging used to identify p53 activators

New prostacyclin receptor agonists developed at Astellas

Novel family of metabotropic glutamate receptor agonists developed at Faust

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...